Mullen Y, Hildemann W
Transplantation. 1975 Oct;20(4):281-90. doi: 10.1097/00007890-197510000-00003.
Specific unresponsiveness inducible in newborn Lewis (Le) rats by injection of bone marrow or kidney cells from (Bu x Le)F1 hybrids was tested in adults by allografting of skin or kidneys from strongly incompatible Buffalo (Bu) strain donors. High doses of bone marrow cells (10(7) or more) proved quite effective in procuring indefinite survival of subsequent Bu kidney allografts, but not Bu skin allografts. Kidney allografts remained fully functional without modulation of their inherent immunogenicity regardless whether skin allografts were acutely rejected before or after kidney grafting on bone marrow-tolerant recipients. Lower doses of bone marrow cells were either near threshold for induction of specific Bu kidney allograft tolerance (5 x 10(6)) or, conversely, led to increased immunity(1-5 x 106). A strikingly different pattern of reactivity was found in adult Le recipients of Bu skin allografts as shown by only a moderate, but stepwise increase in survival times as a function of increasing allogeneic cell dosage at birth. Allogeneic kidney cells at all doses were surprisingly ineffective in inducing tolerance of either kidney or skin allografts, so the existence of kidney-specific transplantation antigens remains problematical. Lymphocytes from kidney allograft-tolerant recipients showed much reduced but still significant antidonor activity in several tests of cell-mediated immunity in vitro and in vivo. Blocking antibody activity was also demonstrable in these animals. Acquired tolerance (i.e., essential nonreactivity) may not only exist in degrees in either T or B cell pathways but may coexist with specific immunoblocking reactions in a dynamic equilibrium. Instead of tolerance versus enhancement, a new concept of selective specific immunoregulation emerges.
通过注射(布法罗×刘易斯)F1杂种的骨髓或肾细胞在新生刘易斯(Le)大鼠中诱导的特异性无反应性,在成年大鼠中通过移植来自强不相容布法罗(Bu)品系供体的皮肤或肾脏进行了测试。高剂量的骨髓细胞(10^7或更多)被证明在使随后的布法罗肾同种异体移植长期存活方面非常有效,但对布法罗皮肤同种异体移植无效。肾同种异体移植保持完全功能,其固有免疫原性未发生改变,无论皮肤同种异体移植在骨髓耐受受体上进行肾移植之前还是之后被急性排斥。较低剂量的骨髓细胞要么接近诱导特异性布法罗肾同种异体移植耐受的阈值(5×10^6),要么相反,导致免疫增强(1 - 5×10^6)。在布法罗皮肤同种异体移植的成年刘易斯受体中发现了一种明显不同的反应模式,表现为随着出生时同种异体细胞剂量的增加,存活时间仅适度但逐步增加。所有剂量的同种异体肾细胞在诱导肾或皮肤同种异体移植耐受方面都出奇地无效,因此肾特异性移植抗原的存在仍然存在问题。来自肾同种异体移植耐受受体的淋巴细胞在体外和体内的几种细胞介导免疫测试中显示出抗供体活性大大降低但仍很显著。在这些动物中也可证明存在阻断抗体活性。获得性耐受(即基本无反应性)可能不仅在T或B细胞途径中存在程度差异,而且可能与特异性免疫阻断反应在动态平衡中共存。不是耐受与增强,而是出现了选择性特异性免疫调节的新概念。